Compare · NVO vs ZBIO
NVO vs ZBIO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zenas BioPharma Inc. (ZBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZBIO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 97.9x ZBIO ($2.20B).
- Over the past year, NVO is down 13.5% and ZBIO is up 92.9% - ZBIO leads by 106.5 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for ZBIO).
- NVO has more recent analyst coverage (25 ratings vs 9 for ZBIO).
- Company
- Novo Nordisk A/S
- Zenas BioPharma Inc.
- Price
- $47.83-1.69%
- $32.72-3.08%
- Market cap
- $215.46B
- $2.20B
- 1M return
- -6.11%
- +1.49%
- 1Y return
- -13.54%
- +92.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZBIO
- Amendment: SEC Form SCHEDULE 13D/A filed by Zenas BioPharma Inc.
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Zenas BioPharma Inc.
- SEC Form 10-Q filed by Zenas BioPharma Inc.
- Zenas BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Nunn Jason Raleigh
- SEC Form 4 filed by Director Lu Hongbo
- SEC Form 4 filed by Officer Moulder Leon O Jr